Evidence map›Paper›PMID 37741955›Full record

ArticleCancer chemotherapy and pharmacology2024

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells.

Man-Yuan Li, Jiao Zhang, Xiao Lu, Dong Zhou, Xu-Feng Deng, Quan-Xing Liu, Ji-Gang Dai, Hong Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts.Medical oncology (Northwood, London, England) · 2025
    Article
  5. Doramectin Induces Apoptosis in B16 Melanoma Cells.Anti-cancer agents in medicinal chemistry · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Man-Yuan Li *Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Jiao Zhang *Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Xiao LuDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Dong ZhouDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Xu-Feng DengDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Quan-Xing LiuDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China.
Ji-Gang DaiDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China. daijigang@tmmu.edu.cn.
Hong ZhengDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, People's Republic of China. ziecoe@tmmu.edu.cn.ORCID 0000-0003-3725-4541
Army Medical University · CN

Funding

Excellent Talent Program of Chongqing cstc2022ycjh-bgzxm0109Key Project of Frontier Science Research of Chinese Academy of Sciences cstc2018jcyjAX0205National Natural Science Foundation of China 81972190
6 · The paper itself

Abstract

introductionLUAD (Lung adenocarcinoma), the most common subtype of lung carcinoma and one of the highest incidences and mortality cancers in the world remains still a substantial treatment challenge. Ivermectin, an avermectin derivative, has been traditionally used as an antiparasitic agent in human and veterinary medicine practice during the last few decades. Though ivermectin has been shown to be effective against a variety of cancers, however, there is few available data reporting the antitumor effects of ivermectin in LUAD.

methodsThe effect of ivermectin on cell viability and proliferative ability of LUAD cells was evaluated using CCK-8 and colony formation assay. Apoptosis rate and autophagy flux were detected using flow cytometry based on PI/Annexin V staining and confocal laser scanning microscope based on LC3-GFP/RFP puncta, respectively. Western blotting experiment was conducted to verify the results of changes in apoptosis and autophagy. LUAD-TCGA and GEO databases were used to analyse the expression and predictive value of PAK1 in LUAD patients. Xenograft model and immumohistochemical staining were used for verification of the inhibitor effect of ivermectin in vivo.

resultsIvermectin treatment strikingly impeded the colony formation, and the viability of the cell, along with cell proliferation, and caused the apoptosis and enhanced autophagy flux in LUAD cells. In addition, ivermectin-induced nonprotective autophagy was confirmed by treating LUAD cells with 3-MA, an autophagy inhibitor. Mechanistically, we found that ivermectin inhibited PAK1 protein expression in LUAD cells and we confirmed that overexpression of PAK1 substantially inhibited ivermectin-induced autophagy in LUAD cells. Based on TCGA and GEO databases, PAK1 was highly expressed in LUAD tissues as compared with normal tissues. Furthermore, LUAD patients with high PAK1 level have poor overall survival. Finally, in vivo experiments revealed that ivermectin efficiently suppressed the cellular growth of LUAD among nude mice.

conclusionThis study not only revealed the mechanism of ivermectin inhibited the growth of LUAD but also supported an important theoretical basis for the development of ivermectin during the therapy for LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsApoptosisAutophagyCell ProliferationHumansIvermectinMiceMice, Nudep21-Activated KinasesIvermectinp21-Activated KinasesPAK1 protein, humanApoptosisAutophagyIvermectinLung adenocarcinomaPAK1

Identifiers

PMID37741955
OpenAlexW4386986044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.